Status:
UNKNOWN
Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.
Lead Sponsor:
Cairo University
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The study aims to compare the effect of intravitreal non steroidal anti inflammatory (Diclofenac) versus the standard treatment of diabetic macular edema, intravitreal anti vascular endothelial growth...
Detailed Description
Thirty eyes of diabetic patients with diabetic retinopathy with macular edema will be randomized using simple randomization method into two groups; A and B. Group A will undergo intravitreal injectio...
Eligibility Criteria
Inclusion
- Diabetic retinopathy with non tractional maculopathy, where central macular thickness is greater than 400µm, with and without cystic changes.
- Diabetes Mellitus type one and two
- Best Corrected Visual Acuity \> 0.1 LogMar
Exclusion
- Patients treated with diclofenac, Ranibizumab or Bevacizumab in the past 3 months
- Patients with a history of branch or central retinal artery occlusion
- Patients without clear media and adequate pupillary dilation that allows proper fundoscopy and imaging, and patients who are not complaint with the regular visits.
- Visual Significant Cataract
- Evidence of vitreomacular traction or macular ischemia
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03458923
Start Date
January 1 2015
End Date
June 1 2018
Last Update
March 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt